The relationship between buspirone bioavailability and dose in healthy subjects
- 1 April 1985
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 6 (2) , 139-145
- https://doi.org/10.1002/bdd.2510060205
Abstract
Dose dependency of the pharmacokinetics of buspirone, a new anxiolytic agent, was tested in 24 healthy volunteers. Each subject received 10, 20, and 40 mg doses according to a randomized, three‐way crossover design with a 7‐day interval between treatments. Buspirone AUC values at 10, 20, and 40 mg doses were in the ratio of 1:1.7:3.5 while Cmax values, had a ratio of 1:1.9:3.7. The dose normalized (10 mg basis) AUC and Cmax values, Tmax values, and half‐lives were not significantly different (p > 0.05) among the doses. Buspirone half‐life did not change as a function of dose (mg kg−1). It was concluded that buspirone exhibits linear pharmacokinetics following doses in the therapeutic range.Keywords
This publication has 4 references indexed in Scilit:
- Dopamine and antianxiety activityPharmacology Biochemistry and Behavior, 1982
- The comparative efficacy of buspirone and diazepam in the treatment of anxietyAmerican Journal of Psychiatry, 1979
- The Analysis of the Two-Period Repeated Measurements Crossover Design with Application to Clinical TrialsBiometrics, 1977